Ottobock SE & Co. KGaA risk profile
41 Elevated one input has moved against it
Measured 20 October 2026 from OBCK's filed statements. Recomputed nightly.
41 (Elevated), driven by Competitive position at 56, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 51 | Elevated | Stable | One-year price volatility — 37.2% |
| Operating pressure | 24 | Normal | Stable | Costs outgrowing revenue — -4.3 percentage points |
| Cash conversion | 16 | Contained | Easing | Capital spending against operating cash — 0.33x |
| Leverage and coverage | 36 | Normal | Easing | Net debt to EBITDA — 3.48x |
| Competitive position | 56 | Elevated | Stable | R&D-intensity gap against peers — -13.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Ottobock SE & Co. KGaA